Drugs / NHS-IL12
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 missed | ||||||
| Phase 1 | NCT04756505 | Mar 2021 → Feb 2022 | female breast carcinoma, hormone receptor-positive breast cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT02994953 | Jan 2017 → Oct 2020 | cancer | EMD Serono Research & Development Institute, Inc. | Terminated | Missed primary |
| Phase 1 | NCT01417546 | Dec 2011 → Jun 2021 | epithelial neoplasm, mesenchymal cell neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04327986 | Jun 2021 → Jan 2022 | pancreatic adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04287868 | Jun 2020 → Jul 2022 | anal carcinoma, cervical cancer, oropharyngeal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04491955 | Sep 2020 → Oct 2022 | colorectal cancer, small intestine cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-05-18 | EMD Serono Research & Development Institute, Inc. | Results Data from EMD Serono’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21 emdserono.com ↗
Data from this NCI-led Phase II clinical study of patients with advanced HPV 16+ cancers provided early evidence of the clinical activity of a triple combination of bintrafusp alfa, NHS-IL12 and PDS0101, with a manageable safety profile. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-05-18 | EMD Serono Research & Development Institute, Inc. | Data from EMD Serono’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21 emdserono.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NHS-IL12 | “The NHS-IL12 (M9241) immunocytokine is composed of 2 interleukin-12 (IL-12) heterodimers, each fused to one of the H-chains of the NHS76 antibody, which has affinity for both...” NCT04327986 ↗6“A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)” NCT02994953 ↗ “NHS-IL12 is a first-in-class, recombinant fusion protein composed of the human monoclonal antibody NHS76” PMID 36640137 ↗ Apr 2023 “Drug: NHS-IL-12” NCT01417546 ↗ |
| Known as | M9241 | “Some will also get NHS-IL12 (M9241).” NCT04491955 ↗ |
| Modality | Protein / enzyme biologic | “NHS-IL12 is a first-in-class, recombinant fusion protein composed of the human monoclonal antibody NHS76” PMID 36640137 ↗ Apr 2023 |
| Route | Subcutaneous | “NHS-IL12 administered subcutaneously every 4 weeks” NCT01417546 ↗ |